Cargando…

PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization

INTRODUCTION: There is controversy surrounding the value of bilateral inferior petrosal sinus sampling (BIPSS) for tumor lateralization in Cushing's disease (CD). We compare lateralization results between BIPSS and pituitary imaging against gold-standard surgical localization. METHODS: A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundholm, Michelle D, Pantalone, Kevin M, Rao, Pratibha, Hamrahian, Amir H, Yogi-Morren, Divya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625442/
http://dx.doi.org/10.1210/jendso/bvac150.1128
_version_ 1784822497581989888
author Lundholm, Michelle D
Pantalone, Kevin M
Rao, Pratibha
Hamrahian, Amir H
Yogi-Morren, Divya
author_facet Lundholm, Michelle D
Pantalone, Kevin M
Rao, Pratibha
Hamrahian, Amir H
Yogi-Morren, Divya
author_sort Lundholm, Michelle D
collection PubMed
description INTRODUCTION: There is controversy surrounding the value of bilateral inferior petrosal sinus sampling (BIPSS) for tumor lateralization in Cushing's disease (CD). We compare lateralization results between BIPSS and pituitary imaging against gold-standard surgical localization. METHODS: A retrospective chart review was conducted in patients with pathology-confirmed CD, visible tumor on MRI (with and without contrast), and who underwent BIPSS at our institution between 2003-2020. An inferior petrosal sinus to peripheral (IPS/P) prolactin ratio >1.8 was used to confirm appropriate IPS sampling. An inter-sinus ACTH gradient ratio greater than 1.4, adjusted for prolactin where available, was used to determine lateralization. In each case, the neurosurgeon performed a full pituitary gland exploration to avoid missing any tumors despite visible tumor on MRI. Descriptive statistics were used. RESULTS: Of 32 patients with CD, visible tumor on MRI, and BIPSS testing, 27 (84%) patients had technically successful bilateral IPSS catheterization and are the subjects of this study. All 27 of these patients had IPS/P ACTH ratio greater than 2 at baseline or 3 after CRH stimulation, consistent with CD, and all 27 lateralized. The median age at diagnosis was 42 years (range 21-69 years) and 85% were female (N=23). The median tumor size on MRI was 5 mm (range 3-8 mm). In 22/27 (81%) patients, the result of the IPSS lateralization was concordant with MRI findings. When MRI and BIPSS lateralization agreed, 21/22 (95%) were confirmed by surgical pathology. Of the 5 cases where MRI and BIPSS disagreed on laterality, the operative report was consistent with MRI lateralization in 3/5 cases, and bilateral disease in the remaining 2 cases. There were no cases where BIPSS lateralization was correct when MRI lateralization was incorrect. Overall, MRI correctly lateralized 26/27 cases (96%), whereas BIPSS correctly lateralized 23/27 (85%). In the subset of 13 patients with tumors measuring <6mm on MRI, MRI imaging lateralization was correct in all 13 (100%) cases and BIPSS lateralization was correct in 11/13 (85%). Adverse events associated with BIPSS were noted in 4 patients (15%) ranging from hematoma to headache. Among the 5 patients who did not have successful BIPSS cannulization, one experienced the adverse effect of transient severe headache. There were no serious complications. The surgeons performed bilateral sellar exploration in all cases regardless of BIPSS or MRI lateralization results. CONCLUSION: When a tumor is visible on MRI, regardless of its size (≥ 3mm), BIPSS does not add to the accuracy of determining tumor lateralization. BIPSS may best be reserved for situations where the diagnosis of CD is in question. Further studies are required to determine the value of BIPSS in lateralizing the source of CD in patients without visible tumor. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.
format Online
Article
Text
id pubmed-9625442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96254422022-11-14 PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization Lundholm, Michelle D Pantalone, Kevin M Rao, Pratibha Hamrahian, Amir H Yogi-Morren, Divya J Endocr Soc Neuroendocrinology and Pituitary INTRODUCTION: There is controversy surrounding the value of bilateral inferior petrosal sinus sampling (BIPSS) for tumor lateralization in Cushing's disease (CD). We compare lateralization results between BIPSS and pituitary imaging against gold-standard surgical localization. METHODS: A retrospective chart review was conducted in patients with pathology-confirmed CD, visible tumor on MRI (with and without contrast), and who underwent BIPSS at our institution between 2003-2020. An inferior petrosal sinus to peripheral (IPS/P) prolactin ratio >1.8 was used to confirm appropriate IPS sampling. An inter-sinus ACTH gradient ratio greater than 1.4, adjusted for prolactin where available, was used to determine lateralization. In each case, the neurosurgeon performed a full pituitary gland exploration to avoid missing any tumors despite visible tumor on MRI. Descriptive statistics were used. RESULTS: Of 32 patients with CD, visible tumor on MRI, and BIPSS testing, 27 (84%) patients had technically successful bilateral IPSS catheterization and are the subjects of this study. All 27 of these patients had IPS/P ACTH ratio greater than 2 at baseline or 3 after CRH stimulation, consistent with CD, and all 27 lateralized. The median age at diagnosis was 42 years (range 21-69 years) and 85% were female (N=23). The median tumor size on MRI was 5 mm (range 3-8 mm). In 22/27 (81%) patients, the result of the IPSS lateralization was concordant with MRI findings. When MRI and BIPSS lateralization agreed, 21/22 (95%) were confirmed by surgical pathology. Of the 5 cases where MRI and BIPSS disagreed on laterality, the operative report was consistent with MRI lateralization in 3/5 cases, and bilateral disease in the remaining 2 cases. There were no cases where BIPSS lateralization was correct when MRI lateralization was incorrect. Overall, MRI correctly lateralized 26/27 cases (96%), whereas BIPSS correctly lateralized 23/27 (85%). In the subset of 13 patients with tumors measuring <6mm on MRI, MRI imaging lateralization was correct in all 13 (100%) cases and BIPSS lateralization was correct in 11/13 (85%). Adverse events associated with BIPSS were noted in 4 patients (15%) ranging from hematoma to headache. Among the 5 patients who did not have successful BIPSS cannulization, one experienced the adverse effect of transient severe headache. There were no serious complications. The surgeons performed bilateral sellar exploration in all cases regardless of BIPSS or MRI lateralization results. CONCLUSION: When a tumor is visible on MRI, regardless of its size (≥ 3mm), BIPSS does not add to the accuracy of determining tumor lateralization. BIPSS may best be reserved for situations where the diagnosis of CD is in question. Further studies are required to determine the value of BIPSS in lateralizing the source of CD in patients without visible tumor. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9625442/ http://dx.doi.org/10.1210/jendso/bvac150.1128 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Lundholm, Michelle D
Pantalone, Kevin M
Rao, Pratibha
Hamrahian, Amir H
Yogi-Morren, Divya
PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title_full PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title_fullStr PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title_full_unstemmed PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title_short PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
title_sort pmon152 in patients with cushing's disease and a visible tumor on mri, ipss does not add to the accuracy of predicting tumor lateralization
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625442/
http://dx.doi.org/10.1210/jendso/bvac150.1128
work_keys_str_mv AT lundholmmichelled pmon152inpatientswithcushingsdiseaseandavisibletumoronmriipssdoesnotaddtotheaccuracyofpredictingtumorlateralization
AT pantalonekevinm pmon152inpatientswithcushingsdiseaseandavisibletumoronmriipssdoesnotaddtotheaccuracyofpredictingtumorlateralization
AT raopratibha pmon152inpatientswithcushingsdiseaseandavisibletumoronmriipssdoesnotaddtotheaccuracyofpredictingtumorlateralization
AT hamrahianamirh pmon152inpatientswithcushingsdiseaseandavisibletumoronmriipssdoesnotaddtotheaccuracyofpredictingtumorlateralization
AT yogimorrendivya pmon152inpatientswithcushingsdiseaseandavisibletumoronmriipssdoesnotaddtotheaccuracyofpredictingtumorlateralization